Autologous blood clot was used to produce pulmonary macroembolism, and lycopodium spores to produce microembolism in nolmal mongrel dogs. Pressures were recorded from the pulmonary artery, left atrium and femoral artery; cardiac output and pulmonary blood volume (PBV) were determined using sequential indicator dilution curves from injections into the pulmonary artery and left atrium. Macro-and microembolism caused comparable elevations of pulmonary artery pressure and total pulmonary resistance. Macroembolism with blood clots resulted in marked decreases in PBV and pulmonary vascular compliance. However, microembolism with lycopodium spores caused only small decreases in PBV despite a large reduction in pulmonary vascular compliance. Prostaglandin E1 infusion after microembolism had no effect on pulmonary hemodynamics, but caused significant systemic hypotension. After macroembolism PGE1 infusion decreased PBV and decreased systemic arterial pressure. The present study reports the response of pulmonary blood volume, vascular compliance, and flows to embolization with macro-and micropulmonary emboli. In addition, the hemodynamic effects of a known pulmonary vasodilator, Prostaglandin E1 (PGE1), were measured following both forms of embolism. 6' 7 Material and Methods Normal mongrel dogs (16-24 kg) were hghtly anesthetized with pentobarbital, 32 mg/kg intraperitoneally, and were placed in the supine position on a fluoroscopic table. Additional small doses of pentobarbital were given intraperitoneally as needed during each experiment, but these administrations were always separated from experimental maneuvers by at least a 30 min delay. The dogs breathed room air spontaneously.
Additional Indexing Words:
Macroembolism Microembolism E XPERIMENTAL PULMONARY EMBOLISM may produce elevation in pulmonary arterial pressure via two mechanisms. Evidence indicates that emboli larger than 100 micra in diameter (macroemboli) cause pulmonary hypertension by mechanical blockade of pulmonary arteries; pulmonary hypertension develops only when more than 50% of these vessels are occluded.1' 2, 3 When emboli smaller than 100 micra in diameter (microemboli) lodge in arterioles and capillaries the resultant elevation of pulmonary arterial pressures appears to be the result of vasoconstriction superimposed on mechanical obstruction. 2 4 The effect of experimental pulmonary embolism on pulmonary blood volume and pulmonary vascular compliance has not been thoroughly investigated.2 This is particularly true for microemboli. Moreover, although pulmonary vasodilators have been found to be ineffective in reversing the Prostaglandin hemodynamic abnormalities caused by experimental macro-pulmonary embolism, equivalent studies have not been performed involving microemboli. 5 The present study reports the response of pulmonary blood volume, vascular compliance, and flows to embolization with macro-and micropulmonary emboli. In addition, the hemodynamic effects of a known pulmonary vasodilator, Prostaglandin E1 (PGE1), were measured following both forms of embolism. 6' 7 Material and Methods Normal mongrel dogs (16-24 kg) were hghtly anesthetized with pentobarbital, 32 mg/kg intraperitoneally, and were placed in the supine position on a fluoroscopic table. Additional small doses of pentobarbital were given intraperitoneally as needed during each experiment, but these administrations were always separated from experimental maneuvers by at least a 30 min delay. The dogs breathed room air spontaneously.
Periodic "spot checks" of femoral arterial P02, PC02, and pH were obtained and analyzed on an IL pH/gas analyzer, model 113 to insure that the animal was ventilating adequately.
Standard USCI #8 Cournand catheters were positioned under fluoroscopic control in the right atrium, main pulmonary artery and through the mitral valve into the left atrium via the aorta and left ventricle. A polyethylene cannula (internal diameter 2 mm) was inserted into one femoral artery. Phasic and mean pressures were monitored by means of P23db Statham lead II of the electrocardiogram by a Sanborn recorder. The strain-gauges were placed at the mid-chest level. The position of all catheters was verified fluoroscopically and with pressure control during each experiment. Cardiac output and pulmonary blood volume (PBV) were determined using sequential, rapid, hand injections of freshly prepared cardiogreen (2.5 mg/ml) into the main pulmonary artery and left atrium.8 Blood was withdrawn from the femoral artery through a Gilford densitometer at 24.7 ml/min by a Harvard Withdrawal Pump. Mean transit time (MTT) and cardiac output (CO) were calculated using the method of Hamilton.9 Pulmonary blood volume was calculated employing the mean transit time from the two sequential dye curves as described by PGE1t was. first dissolved in 95% ethanol (10 mg/ml).
This prostaglandin and ethanol solution was then mixed with 0.2% (Na)2C03 buffer solution, using 0.9 ml of the buffer solution per 0.1 ml of the prostaglandin and ethanol solution. This buffered prostaglandin stock solution was stored at 0°C between experiments. At the time of its use, varying doses of PGE1 were diluted in *Simplastin, Warner-Chilcott. tThe prostaglandins employed in this study were kindly supplied by Dr. J. E. Pike, the Upjohn Co., Kalamazoo, Michigan.
Circulation, Volume XLIX, January 1974 50 ml of 0.9% NaCl solution and were infused into the right atrium by a Harvard Continuous Infusion Pump at a rate of 3.82 ml/min. Pressure, flow, and volume measurements were made immediately after blood clot or spore injections had been completed. Then PGE1 in varying doses (0.04-6.0 mcg/kg/min) was infused and hemodynamic measurements were repeated. Another set of measurements was made approximately 30 min after the termination of the PGE, infusion at a time when pulmonary arterial pressure had returned to near normal. Dogs receiving macroemboli were given the same doses of PGE1 as those receiving microemboli. Measurements were made after pressures and heart rate had maintained a stable value for three to four minutes. This generally occurred after five to seven minutes of the infusion. The pressure values reported below were taken at the time of the dye curves.
Total pulmonary resistance (TPR) was used rather than pulmonary vascular resistance (PVR) because it was difficult to obtain acceptable left atrial pressure in nine of the seventeen dogs, presumably because nary blood volume, nor in cardiac output, total pulmonary resistance or heart rate.
Discussion
The pulmonary vascular bed is vulnerable to extensive passive as well as active hemodynamic alterations. Yu Even though microembolism resulted in pulmonary hypertension of the same magnitude as macroembolism, the decrease in pulmonary blood volume was much less after microembolism. This minimal decrease in pulmonary blood volume after microembolism reflects the fact that a much smaller cross-sectional area of the pulmonary vasculature was compromised by occlusion and/or vasoconstriction of pulmonary arterioles.
Pulmonary vasodilators such as isoproterenol and aminophylline have found some limited clinical use in patients with pulmonary embolism. However, these agents have significant effects on the peripheral circulation and they frequently cause ventricular arrythmias. PGE1 was selected for testing as a therapeutic agent in experimental pulmonary embolism because it is an active pulmonary vasodilator free of arrythmogenic properties. 6, 7 PGE1 infusions following microembolism produced little or no change in pulmonary blood volume and pulmonary vascular compliance despite the fact that mean femoral arterial pressure and total systemic resistance decreased. This lack of change in pulmonary blood volume despite considerable peripheral circulatory vasodilatation would seem to reflect the end result of two opposing hemodynamic processes induced by PGE1 infusion: some active pulmonary vasodilatation occurring in pulmonary arterioles put into vasospasm by lycopodium microemboli2' 4 14 together with passive pulmonary vascular shrinkage secondary to a redistribution of blood from the lungs to the periphery. This explanation is supported by previous observations that PGE1 causes marked active vasodilatation of the peripheral circulation and mild active vasodilatation of the pulmonary circulation.6 7 In dogs embolized with autologous blood clot, PGE1 caused a further reduction in pulmonary blood volume, indicating passive shrinkage of the pulmonary vascular bed. These observations can be explained solely by a redistribution of blood from pulmonary to systemic circulatory beds during PGE1 infusion. The fact that PGE1 increases pulmonary blood volume in the undisturbed canine Iung7 but decreases pulmonary blood volume in the macroembolized pulmonary circulation suggests that the pulmonary vascular bed is not vasoconstricted following macroembolism. These observations lend further support to the concept that macroembolism produces hemodynamic alterations primarily through mechanical blockage of the pulmonary arterial circuit.2 15, 16 Since pulmonary embolism in man is primarily macroembolism, it seems quite unlikely that the prostaglandin, PGE1, would have a beneficial Circulation, Volume XLIX, January 1974 hemodynamic effect in patients with pulmonary embolism.
